TP53 and prostate cancer: In earlier studies, our TMA enabled us to validate several biomarkers with importance for prostate cancer, such as p53 expression [38], PTEN inactivation [32], CRISP3 overexpression [39] or deletions at 6q15 [31] and 5q21 [30].